Anti-Human HLA-DR – Purified In vivo GOLD™ Functional Grade

Pricing & Details

  
Clone
L243
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Major Histocompatibility Class II, MHC class II, HLA-DR Monomorphic
Isotype
Mouse
IgG2a
Applications
B
,
CODEX®
,
CyTOF®
,
IHC FF
,
WB
Prod No.
Size
Price
Avail.
Qty
Add to cart
H261-1.0 mg
1.0 mg
$95.00
In stock
H261-5.0 mg
5.0 mg
$298.00
In stock
H261-25 mg
25 mg
$775.00
In stock
H261-50 mg
50 mg
$1,275.00
In stock
H261-100 mg
100 mg
$1,998.00
In stock
  

Antibody Details

Reactivity Species
Human
Host Species
Mouse
Immunogen
Unknown
Product Concentration
≥ 2.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Purity
>95% by SDS-PAGE and HPLC
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Other Applications Reported In Literature ?
CODEX®, CyTOF®
Each investigator should determine their own optimal working dilution for specific applications.

Description

Specificity
Mouse Anti-Human HLA-DR (Clone L243) recognizes/reacts with the HLA-DR antigen, a member of MHC class II molecules. It does not cross-react with HLA-DP and HLA-DQ. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution
The HLA-DR antigen is present on B-lymphocytes, activated T-lymphocytes and activated natural killer (NK) lymphocytes. This antigen is also expressed on monocytes, macrophages, human progenitor cells and B-cell lymphomas.
Background
HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD (heavy) chain & a 27 kD (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, and dendritic cells. HLA-DR is critical for efficient peptide presentation to CD4+ T cells. Clone L243 binds a conformational epitope on HLA-DRα which depends on the correct folding of the αβ heterodimer.

Antigen Details

Protein
HLA-DR
Ligand/Receptor
CD3/TCR, CD4
Function
Peptide presentation

References & Citations

1. Wakita, H. et al. (1995) J Invest Dermatol 105:536-542. Article Link
2. Bellone, CJ. et al. (1996) J Clin Invest. 97(10):2324-31. PubMed
3. Ikeda Y. et al. (2003) Blood.101(2):621-3. Article Link
4. Lokhorst, HM. et al. (2003) Clin Exp Immunol 131:340–346PubMed
5. Wright, TM. et al. (2000) J Immunol.164(12):6138-46.Article Link
6. Bloem, AC. et al.(2005) Br J Haematol.128(1):73-81.PubMed
7. Wright, TM. et al. (1995) J Clin Invest. 96(1):586-96. PubMed
8. Nishikawa, T. et al. (2000) J Investigative Dermatology 114(1): 88-94. PubMed
9. Wright, TM. et al. (2001) Arthritis Rheum. 44(7):1654-9. PubMed
10. Lampson, LA. et al. (1980) J. Immunol. 125:393
11. Yu, DTY. et al. (1980) J. Exp. Med. 151:91
12. Warnke, R. et al. (1980) N. Eng. J. Med. 303:293
13. Wilkinson, KA. et al. (2005) Infect Immun. 74(5):2991-8
IHC
General Western Blot Protocol
  

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.